Jpmorgan Chase & CO Nexgel, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Nexgel, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 12 shares of NXGL stock, worth $39. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12
Previous 12
-0.0%
Holding current value
$39
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding NXGL
# of Institutions
14Shares Held
233KCall Options Held
0Put Options Held
0-
Geode Capital Management, LLC Boston, MA56.8KShares$188,7080.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA50KShares$165,9170.0% of portfolio
-
Simon Quick Advisors, LLC35.7KShares$118,5730.01% of portfolio
-
Northeast Financial Group, Inc. Tannersville, PA31.8KShares$105,7350.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny28.5KShares$94,4700.0% of portfolio
About NEXGEL, INC.
- Ticker NXGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 5,572,230
- Market Cap $18.5M
- Description
- NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. NEXGEL, Inc. was...